Trending Topic

15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1 Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2 It is conventionally performed via the trans-femoral (TF) route. Recently, however, the trans-radial (TR) route has become the preferred way.3 The TR route offers better procedure comfort, shorter hospitalization […]

Hyo-Soo Kim, ACC 2023: HOST IDEA trial – Short-term dual antiplatelet therapy non-inferior to 12 Months after PCI with third-generation drug-eluting stents

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Mar 29th 2023

The goal of dual antiplatelet therapy (DAPT) is to reduce the risk of stent thrombosis, a potentially life-threatening complication that can occur when blood clots form in the stent. In this touchCARDIO interview, we speak with Prof. Hyo-Soo Kim (Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea) highlights the findings from the HOST IDEA trial investigating the non-inferiority of 3-6 months of DAPT compared to 12 months after percutaneous coronary intervention (PCI) using third-generation drug-eluting stents (DES) with ultrathin struts and advanced polymer technology.

The abstract entitled ‘Comparison Of 3-month Versus 12-month Dual Antiplatelet Therapy After Coronary Intervention Using The Contemporary Drug-eluting Stents With Ultrathin Struts And Advanced Polymer Technology: The Host-idea Randomized Clinical Trialwas presented at ACC.23 Together With WCC (ACC.23/WCC) in New Orleans, 4–6 March 2023.

Interviews in this series:

Prof. Hyo-Soo Kim discusses guidelines for the use of short-term dual antiplatelet therapy after coronary intervention.

Questions:

  1. What are the aims, design and eligibility criteria of the HOST IDEA study? (0:23)
  2. What were the primary and secondary endpoints and how well were they achieved? (2:23)
  3. What were the objectives and findings of the subgroup analyses? (5:32)
  4. How will these findings be used to inform future treatment decisions? (7:38)

Disclosures: Hyo-Soo Kim has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ACC 2023

Access more content on dual antiplatelet therapy

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup